Cancer · Austria
Myeloproliferative neoplasms
How is it diagnosed today? A blood test counts your blood cells. NCI PDQ
What do you need help with?
- Join a trialStudies open to new patients in your country, and abroad if you want.10 open trials in Austria
- Offer tissue or dataGive a sample or your health data to research.
- Get supportPatient groups, money and work, help for family.
- Access and costGetting a treatment that is not on offer here, and who pays.
- Questions for your doctorReady lists to print or copy before your next visit.
- Don't pay for thisOffers with no proof in people, and what to check first.
Where treatment stands
Four steps, from proven to unproven.
Approved in Austria
Usual treatment: Venesection, low-dose aspirin, hydroxyurea. NCI PDQ
7 medicines are approved for this disease in Austria:
- Anagrelide (Anagrelide Viatris, Xagrid, Agrylin) – approved in 2004
- Fedratinib (Inrebic) – approved in 2021
- Imatinib (Glivec, Imatinib Accord, Imatinib Teva) – approved in 2001
- Momelotinib (Omjjara, Ojjaara) – approved in 2024
- Peginterferon alfa-2a (Pegasys) – approved in 2002
- Ropeginterferon alfa-2b (Besremi, BESREMi) – approved in 2019
- Ruxolitinib (Jakavi, Ruxolitinib Viatris, Jakafi) – approved in 2012
An EU approval is valid in Austria. We did not check the national approvals in Austria, so some medicines under “Approved elsewhere” may be approved here too. We did not check whether they are sold or paid for there. Checked in the regulators' own texts on 11 Nov 2026.
Approved elsewhere (5)
- Hydroxycarbamide (Hydrea) – approved for it in France
- Luspatercept (Reblozyl) – approved for it in the US
- Pacritinib (Vonjo) – approved for it in the US
- Pipobroman (Vercyte) – approved for it in France
- Rusfertide (Mimrylo) – approved for it in the US
Being tested in people
10 open trials in Austria, 186 worldwide. See the trials
- 81-mg aspirin once daily (Phase 3)
- 81-mg aspirin twice daily (Phase 3)
- ACE-536 (Phase 3)
- Anagrelide (Phase 3)
Only in the lab or in animals
Not counted yet for this disease.
No proof it works
Animal worm medicines (ivermectin, fenbendazole) for cancer: not approved, and not enough research in people to know if they help. American Cancer Society: What to Know About Ivermectin (21 May 2026) · American Cancer Society: What to Know About Fenbendazole (21 Oct 2025)
Join a trial
Studies that are taking new patients in Austria. The trial team decides who can join. Change the country at the top.
Phase 1: first tests in people · Phase 2: does it help? · Phase 3: compared with the usual treatment
10 open trials in Austria
Tests pelabresib with ruxolitinib in adults with myelofibrosis
NCT07357727 · ClinicalTrials.gov
- Graz – Medical University of Graz
- Salzburg – Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH
- Vienna – Hanusch Krankenhaus der Wiener Gebietskrankenkasse
Age 18 and over
Contact the trial teamTests INCA033989 Against Standard Care in Essential Thrombocythemia
NCT07623200 · ClinicalTrials.gov
- Graz – LKH - Medizinische Universitaet Graz
- Leoben – Landeskrankenhaus (Lkh) Leoben - Standort Leoben
- Linz – Ordensklinikum Linz GmbH Elisabethinen
- and 2 more sites
Age 18 and over
Contact the trial teamLong-term asciminib treatment for people with chronic myeloid leukemia
NCT04877522 · ClinicalTrials.gov
- Graz – Medical University of Graz
- Linz – Ordensklinikum Linz GmbH
- Vienna – Hanusch Krankenhaus der Wiener Gebietskrankenkasse
Ages 7 to 100
Contact the trial teamTests elritercept against placebo for anemia in myelofibrosis
NCT07623161 · ClinicalTrials.gov
- Innsbruck – Medizinische Universitaet Innsbruck
- Linz – Ordensklinikum Linz GmbH
- Vienna – Medical University of Vienna
- and 1 more site
Age 18 and over
Contact the trial teamTests sapablursen with standard care in polycythemia vera
NCT07429266 · ClinicalTrials.gov
- Graz – Medical University of Graz
- Innsbruck – Medizinische Universitaet Innsbruck
- Linz – Ordensklinikum Linz GmbH
- and 2 more sites
Age 18 and over
Contact the trial teamTests oral nuvisertib in people with myelofibrosis
NCT04176198 · ClinicalTrials.gov
- Graz – Medical University of Graz
Age 18 and over
Contact the trial teamTests bezuclastinib in adults with advanced systemic mastocytosis
NCT04996875 · ClinicalTrials.gov
- Vienna – AKH Wien, Universitatsklinikum
Age 18 and over
Contact the trial teamTesting Navtemadlin Added to Ruxolitinib for Myelofibrosis Patients
2023-504724-25-00 · EU Clinical Trials Register
- Graz – Medical University of Graz
- Innsbruck – Medizinische Universitaet Innsbruck
- Linz – Ordensklinikum Linz GmbH
- and 2 more sites
Age 18 and over
Contact the trial teamCompares givinostat with hydroxyurea in high-risk polycythemia vera
NCT06093672 · ClinicalTrials.gov
- Linz – Ordensklinikum Linz GmbH
- Vienna – Medical University of Vienna
- Wels – Klinikum Wels-Grieskirchen GmbH
Age 18 and over
Contact the trial teamTests navtemadlin added to ruxolitinib in myelofibrosis patients with a weak response
NCT06479135 · ClinicalTrials.gov
- Graz – University Hospital Graz, Department of Internal Medicine
- Innsbruck – Medical University Innsbruck, Department of Internal Medicine V (Hematology and Oncology)
- Leoben – Regional Hospital Hochsteiermark - Leoben, Department of Internal Medicine, Department of Hematology and Oncology
- and 4 more sites
Age 18 and over
The registry has not updated this record for a long time. Ask the team whether it is still open.
Contact the trial team
Available abroad (200 trials)
Nearest region first. Travel and treatment abroad are often not paid for; ask your health insurer first.
Tests INCA036978 for safety in people with myeloproliferative neoplasms
NCT07441694 · ClinicalTrials.gov
Countries: Belgium, Germany, Spain and 8 more
- Liège, Belgium – Centre Hospitalier Universitaire (CHU) de Liege
- Roeselare, Belgium – AZ Delta
- Aachen, Germany – University Medical Center Rwth Aachen
Age 18 and over
Contact the trial teamTests LY5830966 in adults with myelofibrosis after a prior JAK2 inhibitor
NCT06343805 · ClinicalTrials.gov
Countries: Spain, France, United Kingdom and 2 more
- Barcelona, Spain – Hospital Clinic de Barcelona
- Madrid, Spain – Hospital Universitario Ramón y Cajal
- Madrid, Spain – Hospital General Universitario Gregorio Marañón
Age 18 and over
Contact the trial teamLong-term bomedemstat use in people with blood disorders who took it before
NCT06351631 · ClinicalTrials.gov
Countries: United Kingdom, Italy, Australia and 2 more
- Boston, United Kingdom – Boston Pilgrim Hospital (Site 3403)
- London, United Kingdom – Guy's & St Thomas' NHS Foundation Trust (Site 3401)
- London, United Kingdom – Imperial College Healthcare NHS Trust - Hammersmith Hospital (Site 3402)
Age 18 and over
Contact the trial teamTests JNJ-88549968 in people with CALR-mutated myeloproliferative neoplasms
NCT06150157 · ClinicalTrials.gov
Countries: Germany, Spain, France and 7 more
- Aachen, Germany – Universitaetsklinikum der RWTH Aachen
- Berlin, Germany – Charité Campus Benjamin Franklin
- Essen, Germany – Med. Universitatsklinik Essen
Age 18 and over
Contact the trial teamTesting Momelotinib with Luspatercept in Transfusion-Dependent Myelofibrosis
NCT06517875 · ClinicalTrials.gov
Countries: Germany, Spain, France and 3 more
- Essen, Germany – Universitaetsklinikum Essen (AoR)
- Jena, Germany – Universitaetsklinikum Jena KöR
- Mannheim, Germany – Universitaetsklinikum Mannheim GmbH
Age 18 and over
Contact the trial teamPRT12396 for Polycythemia Vera and Myelofibrosis, Two Rare Blood Cancers
NCT07469891 · ClinicalTrials.gov
Countries: Spain, France, Italy and 2 more
- Barcelona, Spain – Hospital Clinic de Barcelona
- Madrid, Spain – Hospital Universitario Ramón y Cajal
- Madrid, Spain – Hospital Universitario 12 de Octubre
Age 18 and over
Contact the trial teamStudies immune cells called monocytes in people with myeloproliferative blood disorders
NCT06361641 · ClinicalTrials.gov
Countries: France
- Angers, France – GOUBAND Agathe
- Cholet, France – BESCOND Charles
- Saumur, France – TRUCHAN-GRACZYK Malgorzata
Age 18 and over
Contact the trial teamComparing ruxolitinib with hydroxycarbamide or interferon in polycythemia vera
NCT04116502 · ClinicalTrials.gov
Countries: United Kingdom
- Aberdeen, United Kingdom – Aberdeen Royal Infirmary
- Bath, United Kingdom – Royal United Hospital
- Belfast, United Kingdom – Belfast City Hospital
Age 18 and over
Contact the trial teamFollows people with Philadelphia-negative myeloproliferative neoplasms over time
NCT07863466 · ClinicalTrials.gov
Countries: Italy
- Milan, Italy – Ospedale Maggiore Policlinico
Age 16 and over
Contact the trial teamPacritinib for bone marrow scarring in myelofibrosis with low platelet counts
NCT07394153 · ClinicalTrials.gov
Countries: Spain
- Barcelona, Spain – Hospital Universitari Vall d'Hebron
- Barcelona, Spain – Hospital Clinic de Barcelona
- Barcelona, Spain – Hospital del Mar
Age 18 and over
Contact the trial teamTests selinexor alone in people with myelofibrosis and low platelet counts
2024-511309-47-00 · EU Clinical Trials Register
Countries: Belgium, Bulgaria, Czechia and 8 more
- Leuven, Belgium – UZ Leuven
- Plovdiv, Bulgaria – University Multiprofile Hospital For Active Treatment Saint Georgi EAD
- Sofia, Bulgaria – University Multiprofile Hospital For Active Treatment St. Ivan Rilski EAD
Age 18 and over
Contact the trial teamContinued RVU120 Treatment for Patients From an Earlier Study
NCT06987058 · ClinicalTrials.gov
Countries: Spain, France, Italy and 1 more
- Pamplona, Spain – Clínica Universidad de navarra
- Nice, France – Centre Hospitalier Universitaire de Nice
- Pessac, France – Centre Hospitalier Universitaire de Bordeaux
Age 18 and over
Contact the trial teamTests BGB-11417 alone or with azacitidine in myeloid blood cancers
NCT04771130 · ClinicalTrials.gov
Countries: Germany, Spain, France and 6 more
- Leipzig, Germany – Universitaet Leipzig
- Ulm, Germany – Universitaetsklinikum Ulm AoR
- Barcelona, Spain – Hospital de la Santa Creu i Sant Pau
Age 18 and over
Contact the trial teamTests roginolisib with ruxolitinib in myelofibrosis not responding to JAK inhibitors
2024-515252-20-00 · EU Clinical Trials Register
Countries: Spain, Italy
- Barcelona, Spain – Hospital Universitari Vall d'Hebron
- L'Hospitalet de Llobregat, Spain – Institut Catala D'oncologia
- Madrid, Spain – Hospital Universitario HM Sanchinarro
Age 18 and over
Contact the trial teamRegistry Following People With Blood Disorders Called MDS and Related Conditions
NCT07561385 · ClinicalTrials.gov
Countries: Germany
- Dresden, Germany – Universitätsklinikum Carl Gustav Carus Dresden
Age 18 and over
Contact the trial teamTailored exercise program for people with myeloproliferative neoplasms
NCT07384039 · ClinicalTrials.gov
Countries: Germany
- Hanover, Germany – Hannover Medical School
Age 18 and over
Contact the trial teamTests INCA035784 safety in adults with myeloproliferative neoplasms
NCT07008118 · ClinicalTrials.gov
Countries: Belgium, Germany, Italy and 2 more
- Brussels, Belgium – Cliniques universitaires Saint-Luc
- Ghent, Belgium – Universitair Ziekenhuis Gent
- Leuven, Belgium – Universitaire Ziekenhuizen Leuven
Age 18 and over
Contact the trial teamObservational Study of Ropeginterferon Alfa-2b in Adults With Polycythemia Vera
NCT06506084 · ClinicalTrials.gov
Countries: Italy, Poland
- Alessandria, Italy – A.S.O. SS. Antonio e Biagio e C.Arrigo di Alessandria
- Bari, Italy – Azienda Ospedaliera Universitaria Consorziale - Policlinico, U.O. Ematologia con Trapianto
- Bergamo, Italy – SC Ematologia, ASST Papa Giovanni XXIII
Ages 18 to 100
Contact the trial teamFollowing people with myelofibrosis over time in Europe
NCT06533813 · ClinicalTrials.gov
Countries: Germany, Spain, Italy and 3 more
- Halle, Germany – University Hospital Halle Department of Hematology/Oncology
- Hanover, Germany – University Medicine Hannover
- Minden, Germany – University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care Johannes Wesling Medical Center Minden UKRUB, University of Bochum
Ages 18 to 100
Contact the trial teamStudying adults with essential thrombocythemia who later develop polycythemia vera
NCT07203768 · ClinicalTrials.gov
Countries: Germany, Spain, United Kingdom and 2 more
- Halle, Germany – University Hospital Halle
- Hanover, Germany – Hannover Medical School
- Minden, Germany – University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care Johannes Wesling Medical Center
Ages 18 to 100
Contact the trial teamLong-term safety of luspatercept in people from earlier luspatercept studies
NCT04064060 · ClinicalTrials.gov
Countries: Belgium, Bulgaria, Germany and 19 more
- Brasschaat, Belgium – hospital not given
- Bruges, Belgium – hospital not given
- Ghent, Belgium – hospital not given
Age 18 and over
Contact the trial teamTests roginolisib with ruxolitinib in adults with myelofibrosis
NCT06887803 · ClinicalTrials.gov
Countries: Spain, United Kingdom, Italy
- Barcelona, Spain – Vall d'Hebron University Hospital
- Barcelona, Spain – Avigunda Gran via de l'Hospitalet 199-203, 08908 L'Hospitalet de Llobregat
- Madrid, Spain – START Madrid - CIOCC
Age 18 and over
Contact the trial teamTests STP938 in adults with high risk essential thrombocythaemia
NCT06786234 · ClinicalTrials.gov
Countries: France, United Kingdom
- Brest, France – Chu Brest
- Marseille, France – Institut Paoli-Calmettes
- Nantes, France – CHU Nantes
Age 18 and over
Contact the trial teamChecking how well clopidogrel works in people with essential thrombocythemia
NCT07645755 · ClinicalTrials.gov
Countries: Italy
- Pescara, Italy – Azienda USL di Pescara - Ospedale Santo Spirito
- Torino, Italy – AOU Città della Salute e della Scienza di Torino
Age 18 and over
Contact the trial teamTesting a new genome scan for chromosome changes in Ph-negative myeloproliferative neoplasms
NCT05714592 · ClinicalTrials.gov
Countries: France
- Amiens, France – Centre Hospitalier Universitaire d'Amiens
Age 18 and over
Contact the trial teamStudying immune cell responses to myeloproliferative neoplasms using blood and bone marrow samples
NCT07590986 · ClinicalTrials.gov
Countries: Belgium
- Brussels, Belgium – de Duve Institute, UCLouvain
Age 18 and over
Contact the trial teamTests two ways to prevent graft-versus-host disease after donor stem cell transplant
NCT04888741 · ClinicalTrials.gov
Countries: United Kingdom
- Birmingham, United Kingdom – Queen Elizabeth Hospital
- Bristol, United Kingdom – Bristol Haematology and Oncology Centre
- Cambridge, United Kingdom – Addenbrookes Hospital
Ages 16 to 70
Contact the trial teamRegistry collecting data on rare blood cell overgrowth diseases in children
NCT07410247 · ClinicalTrials.gov
Countries: Germany
- Erlangen, Germany – Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany
Ages 0 to 17
Contact the trial teamStudies how interferon acts on blood stem cells in myeloproliferative neoplasms
NCT05850273 · ClinicalTrials.gov
Countries: France
- Villejuif, France – Inserm U1287
Age 18 and over
Contact the trial teamIadademstat for essential thrombocythemia that no longer responds to hydroxyurea
2025-523864-19-00 · EU Clinical Trials Register
Countries: Spain
- Barcelona, Spain – Hospital del Mar
- Barcelona, Spain – Hospital Universitari Vall d'Hebron
- Barcelona, Spain – Hospital Clinic de Barcelona
Age 18 and over
Contact the trial teamExercise program for fatigue in people with myeloproliferative neoplasms or chronic myeloid leukemia
NCT07518940 · ClinicalTrials.gov
Countries: Italy
- Torino, Italy – AO Ordine Mauriziano di Torino
Age 18 and over
Contact the trial teamStudies immune problems linked to clonal hematopoiesis and VEXAS syndrome
NCT05969821 · ClinicalTrials.gov
Countries: France
- Paris, France – AP-HP, Service de médecine interne, Hôpital Saint Antoine
Age 18 and over
Contact the trial teamTests blood thinners against aspirin to prevent clots in blood disorders
NCT05198960 · ClinicalTrials.gov
Countries: France
- Angers, France – CHU d Angers
- Annecy, France – CH d'ANNECY
- Argenteuil, France – CH d'Argenteuil
Age 18 and over
Contact the trial teamStudying gene mutation patterns in people with myelofibrosis
NCT05710211 · ClinicalTrials.gov
Countries: France
- Angers, France – CHU Angers
- Brest, France – CHRU Brest
- Cholet, France – CH Cholet
Age 18 and over
Contact the trial teamMeasures CALR gene levels in patients with blood cell disorders over time
NCT04942080 · ClinicalTrials.gov
Countries: France
- Angers, France – CHU Angers
- Bordeaux, France – CHU Bordeaux
- Brest, France – Chu Brest
Age 18 and over
Contact the trial teamStudying why some blood disorder patients respond poorly to standard treatment
NCT05440838 · ClinicalTrials.gov
Countries: France
- Angers, France – CHU Angers
- Brest, France – Chu Brest
- Nantes, France – CHU Nantes
Age 18 and over
Contact the trial teamTesting a lab platform that analyzes samples from people with blood cancers
NCT07445438 · ClinicalTrials.gov
Countries: Italy
- Parma, Italy – University of Parma
Age 2 and over
Contact the trial teamGenetic and molecular testing of samples from people with blood cancers
NCT07445984 · ClinicalTrials.gov
Countries: Italy
- Parma, Italy – University of Parma
Age 1 and over
Contact the trial teamNon-invasive blood test and PET scan to track scarring in myelofibrosis
NCT07419178 · ClinicalTrials.gov
Countries: Italy
- Parma, Italy – Dipartimento di Medicina e Chirurgia
Age 18 and over
Contact the trial teamLab testing of tumor samples to profile high-risk blood and solid cancers
NCT07403630 · ClinicalTrials.gov
Countries: Italy
- Palermo, Italy – AO Riuniti Villa Sofia-Cervello di Palermo
- Perugia, Italy – University of Perugia
Age 1 and over
Contact the trial team
Showing 40 of 200. Use the filters to narrow the list.
How to get into an early trial
- A lab does not treat patients, so you cannot phone the lab to get a new treatment.
- Ask your doctor to look at phase 1 trials with you. These are the first tests in people.
- If one fits, your doctor sends a referral to the trial centre.
- The trial team checks whether you can join and decides.
Trial data: ClinicalTrials.gov, courtesy of the U.S. National Library of Medicine; it does not endorse this site. EU trials: EU Clinical Trials Information System (CTIS), European Medicines Agency. We show the registry records; the trial team has the last word on who can join.
Latest research
The five newest articles. The label comes from the PubMed index: whether it was tested in people, in animals or only in the lab.
- CAR-T Targeting of Mutant Calreticulin Selectively Eradicates Myeloproliferative Neoplasm-Sustaining Stem Cells.Blood · 2026-11-12
- In peopleHow I diagnose myeloid or lymphoid neoplasms with tyrosine kinase gene fusions.Am J Clin Pathol · 2026-11-04
- Low dose pre-transplant splenic radiotherapy for myeloproliferative neoplasms.Leuk Lymphoma · 2026-11-11
- Transfusion-related cost and time burden offsets associated with pacritinib versus best available therapy in patients with myelofibrosis: an economic evaluation based on the PERSIST-2 trial.Future Oncol · 2026-11-11
- The new Iron Age in polycythemia vera.Blood · 2026-11-12
Is it true?
Saw something on social media? Fact-check it now.
Get screened
For family members and people at higher risk: free checks can find some cancers early, before there are symptoms.
There is no routine screening for this cancer. If you have symptoms or a family history, talk to your doctor.
If several people in your family had cancer, ask your GP whether genetic counselling makes sense for you.
Offer tissue or data
You can help research move faster.
Give tissue or blood to research
Before an operation or a blood test, ask if left-over tissue or blood can go to a biobank.
- Does this hospital have a biobank?
- What will the sample be used for, and for how long?
- Can I change my mind later?
Share your health data
Ask your doctor whether there is a patient registry for your illness. You choose what you share.
Take part as a healthy volunteer
Some studies need people without the illness, often family members.
Volunteer studiesGet support
Patient groups in Austria
- Österreichische Krebshilfe
Free, anonymous counselling at regional centres in every federal state, psycho-oncology and emergency financial aid.
Phone: 01 7966450
- MPN Austria
Austrian patient association for people with myeloproliferative neoplasms (MPN) and their relatives. Member of MPNAN.
Help for every illness in Austria (4)
- 1450 – Rund-um-die-Uhr-Gesundheitsberatung
Austria's nationwide 24/7 telephone health advice line: trained staff assess symptoms and guide callers to the appropriate care.
- Telefonseelsorge Österreich – Notruf 142
Free, confidential 24/7 emotional support and crisis line for anyone in Austria, reachable on 142.
- Gesundheitsportal Österreich (gesundheit.gv.at)
Austria's official public health portal, offering quality-assured information on diseases, prevention, health services and patient rights.
- ARGE Selbsthilfe Österreich
ARGE Selbsthilfe Österreich represents the interests of self-help groups and patient organisations in Austrian social and health policy.
Available abroad: international groups (8)
- MPN Advocacy & Education International
Nonprofit providing education and advocacy for people living with myeloproliferative neoplasms.
- MPN Research Foundation
Foundation funding research into myeloproliferative neoplasms and supporting the MPN patient community.
- European Cancer Patient Coalition (ECPC)
Umbrella of European cancer patient groups, with a patient toolbox and a legal network for cancer patients.
- EURORDIS – Rare Diseases Europe
Alliance of over 1,000 rare disease patient organisations, with a list of rare disease helplines by country.
- MPN Advocates Network
Global network of MPN patient groups: advocacy education, MPN Awareness Day, global patient survey, webinars, MPN Horizons conference.
- Workgroup of European Cancer Patient Advocacy Networks
Network of pan-European cancer patient umbrella groups (including the blood cancer networks): joint advocacy, WECAN Academy training for patient advocates, patient experience data courses.
- European Patients' Forum (EPF)
Umbrella of European patient organisations and national patient coalitions.
- International Alliance of Patients' Organizations
Global alliance of patient organisations of all diseases, promoting patient-centred healthcare.
Money and work
If the illness stops you working, ask the hospital social worker which benefits you can claim.
- Which sick-pay or disability benefits can I apply for?
- Is there help for the carer in the family?
- Are travel costs to treatment paid back?
After a loss
If someone you love has died, you do not have to go through it alone. Many families ask themselves whether they missed something; the care team can talk this through with you.
We have no grief support group in Austria in our list yet. The hospital's social worker or palliative team can tell you where to find one.
Hospitals and hospices have chaplains and counsellors, for any faith or none.
Some families decide to give tissue to research after death, so that the illness can be studied. If you want to, ask the treating hospital early whether it has such a programme.
Access and cost
- If no trial fits, your doctor can ask the company and the medicines authority whether early access (compassionate use) is possible.
- In Austria the medicines agency BASG lists the early-access programmes that are running. BASG (Austria): list of compassionate use programmes, no. 054
- In the EU you may get planned care in another EU country. Ask your health insurer before you go. Your Europe: planned medical treatment abroad
- Some medicines for this disease are approved abroad but maybe not here: see “Approved elsewhere” under “Approved in Austria” above.
Don't pay for this
No one will cure you through a Facebook message or ask you to invest money.
- Animal worm medicines bought online (ivermectin, fenbendazole)
They are made for animals and not tested for cancer in people. High doses can cause seizures or coma, fenbendazole has caused liver damage, they may weaken your cancer treatment, and they can keep you out of a trial.
American Cancer Society: What to Know About Ivermectin (21 May 2026) · American Cancer Society: What to Know About Fenbendazole (21 Oct 2025) · ASCO: Oncologists urged to discuss ivermectin and fenbendazole (17 Jun 2026)
- “Treatment plans” offered in comments
Ask which published study in people is behind it. Usually there is none.
- Anyone who answers your post with a private treatment
Real trials are listed in a public registry. Check the number on ClinicalTrials.gov or the EU trial register.
- Strangers offering investments or “funds” for treatment
Do not reply and do not send money. Report the comment or message.
Before you pay for anything, ask three things
- Can I have a written price, with everything that is included?
- Which published study in people shows it helps my disease?
- What does my doctor say about it?
Questions for your doctor
Ready lists for a new diagnosis, during treatment, before a trial and before you pay. Open the question lists
Not medical advice. We show what is open and what is known; your care team decides what fits you.